Latest News and Press Releases

12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September        Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline ...

GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial...

AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteersAltimmune will discontinue further development of AdCOVID and focus its resources on its ongoing...

Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment targetAscending multi-dose regimen well-tolerated without necessity for...

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during...

Similar Neutralization Titers Observed for Both Ancestraland B.1.351 South African Variant Phase I Clinical Trial of AdCOVID Expected to Report Data in June 2021 GAITHERSBURG, Md., May 26, 2021 ...

Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June        Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline GAITHERSBURG, Md., May 17,...

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial...

Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2 Sterilizing Immunity Believed to be Critical for Blocking Viral Transmission ...

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...